Serum 25-Hydroxy Vitamin D and Prostate Cancer Risk in a Large Nested Case-Control Study., Cancer Epidemiol Biomarkers Prev 20: 1850-60
view abstract
Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer, PLoS One 6: 6
view abstract
Long-term variation in serum 25-hydroxyvitamin D concentration among participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, Cancer Epidemiol Biomarkers Prev 19: 927-31
view abstract
Vitamin D deficiency and insufficiency among patients with prostate cancer, BJU Int 104: 909-14
view abstract
Serum vitamin D concentration and prostate cancer risk: a nested case-control study, J Natl Cancer Inst 100: 796-804
view abstract
Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk., Prostate 67: 911-23
view abstract
A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer, PLoS Med 4: e103
view abstract
Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer., J Steroid Biochem Mol Biol 89: 533-7
view abstract
Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer., Cancer Causes Control 15: 255-65
view abstract
Circulating vitamin D metabolites in relation to subsequent development of prostate cancer., Cancer Epidemiol Biomarkers Prev 5: 121-6
view abstract
Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States), Cancer Causes Control 6: 235-9
view abstract
